BKCa Channel Activation Attenuates the Pathophysiological Progression of Monocrotaline-Induced Pulmonary Arterial Hypertension in Wistar Rats
ConclusionThe use of a selective and potent opener to activate the BKCa channels promoted improvement of haemodynamic parameters and consequent prevention of RV maladaptive remodelling in rats with MCT-induced PAH. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - July 8, 2021 Category: Cardiology Source Type: research

Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-Analysis
AbstractPurposeData on the relationship between omega-3 fatty acid (n-3 FA) therapy with atrial fibrillation (AF) have been inconsistent. We investigate the association between n-3 FA and risk for AF by pooling data from available large, cardiovascular outcome trials.MethodsWe performed a systematic search on PubMed and Embase for studies on n-3 FA with AF as an outcome measure. Large ( ≥ 1000 participants) randomized controlled trials with ≥ 1-year follow-up period were included. The association between n-3 FA and risk of AF or stroke was assessed. Mantel–Haenszel random effects model was ...
Source: Cardiovascular Drugs and Therapy - July 8, 2021 Category: Cardiology Source Type: research

Ticagrelor and Dapagliflozin Have Additive Effects in Ameliorating Diabetic Nephropathy in Mice with Type-2 Diabetes Mellitus
ConclusionsDapagliflozin and ticagrelor attenuated the progression of diabetic nephropathy in BTBR ob/ob mice with additive effects of the combination. This was associated with AMPK activation and reduced activation of the NLRP3 inflammasome, whereas only dapagliflozin increased Akt activation. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - July 7, 2021 Category: Cardiology Source Type: research

Correction to: RIC in COVID-19 —a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19
AbstractA Correction to this paper has been published:https://doi.org/10.1007/s10557-021-07223-w (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - July 7, 2021 Category: Cardiology Source Type: research

Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries
AbstractPurposeHigher risk of bleeding with ticagrelor over clopidogrel in elderly patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) has been suggested. We assessed the incidence of major bleedings (MB), reinfarction (re-MI), and all-cause death to evaluate safety and efficacy of ticagrelor versus clopidogrel in such population.MethodsReal-world registries RENAMI and BleeMACS were merged. The pooled cohort was divided into two groups, clopidogrel versus ticagrelor. Statistical analysis considered patients
Source: Cardiovascular Drugs and Therapy - July 5, 2021 Category: Cardiology Source Type: research

The IL-6/STAT Signaling Pathway and PPAR α Are Involved in Mediating the Dose-Dependent Cardioprotective Effects of Fenofibrate in 5-Fluorouracil-Induced Cardiotoxicity
ConclusionFEN demonstrated a significant cardioprotective effect against 5FU-induced cardiac damage. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - June 29, 2021 Category: Cardiology Source Type: research

Sotagliflozin Reduces HF Events in T2DM Regardless of Baseline Characteristics, Including HF, CKD and LVEF
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - June 28, 2021 Category: Cardiology Source Type: research

RIC in COVID-19 —a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19
ConclusionsThe results of this pilot study will provide initial evidence on the ability of RIC to suppress the production of inflammatory cytokines in the setting of COVID-19.Trial RegistrationNCT04699227, registered January 7th, 2021. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - June 25, 2021 Category: Cardiology Source Type: research

Efficacy and Safety of Low-Dose Prasugrel Versus Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis
ConclusionsWe found that low-dose prasugrel was not associated with changes in MACE or major bleeding compared with clopidogrel in RCTs. However, analysis of data from observational studies revealed that low-dose prasugrel was associated with an increased risk of major bleeding compared with clopidogrel. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - June 25, 2021 Category: Cardiology Source Type: research

Mirabegron Ameliorated Atherosclerosis of ApoE −/− Mice in Chronic Intermittent Hypoxia but Not in Normoxia
ConclusionThis study first demonstrated that mirabegron impeded the progression of CIH-induced atherosclerosis, at least in part, via β3 AR–mediated oxidative stress, suggesting a promising therapeutic strategy for protecting against atherosclerosis induced by CIH. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - June 21, 2021 Category: Cardiology Source Type: research

Review Article: Gastrointestinal Bleeding Risk with Direct Oral Anticoagulants
ConclusionDOACs as a class do not increase the risk of major gastrointestinal bleeding compared to VKAs, which supports their continued use for different anticoagulant indications. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - June 18, 2021 Category: Cardiology Source Type: research

Early Myocardial Dysfunction and Benefits of Cardiac Treatment in Young X-Linked Duchenne Muscular Dystrophy Mice
ConclusionsThis is the first animal study to evaluate the therapeutic effect of a drug targeting early onset of DMD-related cardiomyopathy, using 2D strain echocardiography. Speckle-tracking analyses revealed early alterations of LV posterior segments that could be prevented by 4  months of RyR2 stabilization.Graphical abstract (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - June 17, 2021 Category: Cardiology Source Type: research

Five Years of Sacubitril/Valsartan —a Safety Analysis of Randomized Clinical Trials and Real-World Pharmacovigilance
ConclusionWith increased uptake of sacubitril/valsartan, risks of hypotension, renal dysfunction, hyperkalemia, and angioedema appear low and acceptable in RCTs and global clinical practice. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - June 14, 2021 Category: Cardiology Source Type: research

Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease
AbstractBisoprolol and nebivolol are highly selective β1-adrenoceptor antagonists, with clinical indications in many countries within the management of heart failure with reduced left ventricular ejection fraction (HFrEF), ischaemic heart disease (IHD), and hypertension. Nebivolol has additional vasodilator actions, related to enhanced release of NO in the vascular wall. In principle, this additional mechanism compared with bisoprolol might lead to more potent vasodilatation, which in turn might influence the effectiveness of nebivolol in the management of HFrEF, IHD and hypertension. In this article, we review the th...
Source: Cardiovascular Drugs and Therapy - June 9, 2021 Category: Cardiology Source Type: research

Dose-Dependent Risk Reduction for Myocardial Infarction with Eicosapentaenoic Acid: a Meta-analysis and Meta-regression Including the STRENGTH Trial
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - June 8, 2021 Category: Cardiology Source Type: research

Switching, Persistence and Adherence to Statin Therapy: a Retrospective Cohort Study Using the Australian National Pharmacy Data
This study aimed to explore the patterns of switching, adherence and persistence among the Australian general population with newly dispensed statins.MethodsA retrospective cohort study was conducted using a random sample of data from the Australian national prescription claims data. Switching, adherence to and persistence with statins were assessed for people starting statins from 1 January 2015 to 31 December 2019. Switching was defined as either switching to another intensity of statin, to another statin or to a non-statin agent. Non-persistence to treatment was defined as discontinuation (i.e. ≥90 days with no ...
Source: Cardiovascular Drugs and Therapy - June 7, 2021 Category: Cardiology Source Type: research

Is the Endothelium the Missing Link in the Pathophysiology and Treatment of COVID-19 Complications?
AbstractPatients with COVID-19 present a wide spectrum of disease severity, from asymptomatic cases in the majority to serious disease leading to critical care and even death. Clinically, four different scenarios occur within the typical disease timeline: first, an incubation and asymptomatic period; second, a stage with mild symptoms due mainly to the virus itself; third, in up to 20% of the patients, a stage with severe symptoms where a hyperinflammatory response with a cytokine storm driven by host immunity induces acute respiratory distress syndrome; and finally, a post-acute sequelae (PASC) phase, which present sympto...
Source: Cardiovascular Drugs and Therapy - June 7, 2021 Category: Cardiology Source Type: research

Atrial High-Rate Episodes in Patients with Devices Without a History of Atrial Fibrillation: a Systematic Review and Meta-analysis
ConclusionThe present systematic review and meta-analysis demonstrated that among patients without a documented history of AF, the detection of AHREs by CIEDs was associated with significant increased risk of clinical AF and stroke.Registration Number (DOI)Available inhttps://doi.org/10.17605/OSF.IO/ZRF6M. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - June 5, 2021 Category: Cardiology Source Type: research

Effects of Major Antihypertensive Drug Classes on Erectile Function: a Network Meta-analysis
ConclusionAll antihypertensive medication classes seem to exert neutral or insignificant effects on EF. Further high-quality studies are needed to better explore the effects of antihypertensive medication on EF. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - May 4, 2021 Category: Cardiology Source Type: research

The Redox Modulating Sonlicromanol Active Metabolite KH176m and the Antioxidant MPG Protect Against Short-Duration Cardiac Ischemia-Reperfusion Injury
ConclusionProtection against cardiac IRI by the antioxidant KH176m is critically dependent on duration of ischemia. The data suggest that with longer ischemia, the capacity of KH176m to reduce cardiac oxidative stress is rate-limiting, irreversible ischemic oxidative damage maximally accumulates, and antioxidant protection is strongly diminished. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 29, 2021 Category: Cardiology Source Type: research

CD36+/CD61+ Microparticles Correlate with the Risk of Percutaneous Cardiac Interventions in Coronary Artery Disease Patients and the Effects of Ticagrelor
AbstractPurposeThe CD36 scavenger receptor is a mediator of both atherogenesis and thrombosis. We aimed to investigate the prognostic value of CD36+ microparticles (MPs) released from platelets for cardiovascular event presentation in coronary artery disease (CAD) patients and the effects of different antiplatelet drugs on MPs.MethodsA total of 101 aspirin-treated CAD patients, who were planned to undergo coronary angiography (CAG), were randomized to either a standard clopidogrel regimen or ticagrelor treatment. Total Annexin V-(AV)+ MPs, CD61+/AV+ MPs, and CD36+/CD61+/AV+ MPs were quantified by flow cytometry at baseline...
Source: Cardiovascular Drugs and Therapy - April 24, 2021 Category: Cardiology Source Type: research

Ang II Promotes SUMO2/3 Modification of RhoGDI1 Through Aos1 and Uba2 Subunits, and then Regulates RhoGDI1 Stability and Cell Proliferation
ConclusionThis study reveals the differences between SUMO2/3 and SUMO1 modification in regulating RhoGDI1 stability and Ang II-mediated cell proliferation.Graphical abstractSchematic summary of roles of SUMO1 and SUMO2/3 modification of RhoGDI1 in regulating RhoGDI1 stability and cell proliferation in Ang II-treated HA-VSMCs. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 23, 2021 Category: Cardiology Source Type: research

Empagliflozin Disrupts a Tnfrsf12a-Mediated Feed Forward Loop That Promotes Left Ventricular Hypertrophy
ConclusionEmpagliflozin attenuates LV enlargement in mice with hypertrophic heart failure. This effect may be mediated, at least in part, by a reduction in loading conditions which limits upregulation of the inducible, proinflammatory, and prohypertrophic TNF superfamily receptor, Tnfrsf12a. Disruption of the Tnfsf12/Tnfrsf12a feed forward system may contribute to the cardioprotective benefits of SGLT2 inhibition.Graphical abstract (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 22, 2021 Category: Cardiology Source Type: research

An Adapted Neural-Fuzzy Inference System Model Using Preprocessed Balance Data to Improve the Predictive Accuracy of Warfarin Maintenance Dosing in Patients After Heart Valve Replacement
This study aimed to create an adapted neural-fuzzy inference system (ANFIS) model using preprocessed balance data to improve the predictive accuracy of warfarin maintenance dosing in Chinese patients undergoing heart valve replacement (HVR).MethodsThis retrospective study enrolled patients who underwent HVR between June 1, 2012, and June 1, 2016, from 35 centers in China. The primary outcomes were the mean difference between predicted warfarin dose by ANFIS models and actual dose and the models ’ predictive accuracy, including the ideal predicted percentage, the mean absolute error (MAE), and the mean squared error (...
Source: Cardiovascular Drugs and Therapy - April 20, 2021 Category: Cardiology Source Type: research

Correction to: Role of Bempedoic Acid in Clinical Practice
A Correction to this paper has been published:https://doi.org/10.1007/s10557-021-07188-w (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 19, 2021 Category: Cardiology Source Type: research

Efficacy and Safety of the Fixed-Dose Versus Variable-Dose of 4-PCC for Vitamin K Antagonist Reversal: A Comprehensive Systematic Review and Meta-Analysis
ConclusionsThe use of a fixed-dose of 4-PCC may be considered an effective and safe dosing strategy for VKAs reversal in various clinical situations. However, further well-designed, controlled studies should be conducted focusing on clinical outcomes to determine the optimal dose of 4-PCC for VKAs reversal. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 17, 2021 Category: Cardiology Source Type: research

Cilostazol: a Review of Basic Mechanisms and Clinical Uses
AbstractPrimarily used in the treatment of intermittent claudication, cilostazol is a 2-oxyquinolone derivative that works through the inhibition of phosphodiesterase III and related increases in cyclic adenosine monophosphate (cAMP) levels. However, cilostazol has been implicated in a number of other basic pathways including the inhibition of adenosine reuptake, the inhibition of multidrug resistance protein 4, among others. It has been observed to exhibit antiplatelet, antiproliferative, vasodilatory, and ischemic-reperfusion protective properties. As such, cilostazol has been investigated for clinical use in a variety o...
Source: Cardiovascular Drugs and Therapy - April 16, 2021 Category: Cardiology Source Type: research

CHOP Increases TRIB3-Dependent miR-208 Expression to Potentiate Vascular Smooth Muscle Cell Proliferation and Migration by Downregulating TIMP3 in Atherosclerosis
ConclusionTaken together, inhibition of CHOP may inhibit the proliferation and migration of VSMCs as well as reduce the levels of TC, TG, and LDL-C but increase the level of HDL-C through the TRIB3/miR-208/TIMP3 axis, thereby inhibiting the progression of atherosclerosis. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 15, 2021 Category: Cardiology Source Type: research

Integration of Transformative Platforms for the Discovery of Causative Genes in Cardiovascular Diseases
AbstractCardiovascular diseases are the leading cause of morbidity and mortality worldwide. Genome-wide association studies (GWAS) are powerful epidemiological tools to find genes and variants associated with cardiovascular diseases while follow-up biological studies allow to better understand the etiology and mechanisms of disease and assign causality. Improved methodologies and reduced costs have allowed wider use of bulk and single-cell RNA sequencing, human-induced pluripotent stem cells, organoids, metabolomics, epigenomics, and novel animal models in conjunction with GWAS. In this review, we feature recent advancemen...
Source: Cardiovascular Drugs and Therapy - April 15, 2021 Category: Cardiology Source Type: research

Translating Cardiovascular Genomics to Clinical Practice
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 14, 2021 Category: Cardiology Source Type: research

The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review
AbstractAimIn recent decades, there has been a revolutionary decrease in cancer-related mortality and an increase in survival due to the introduction of  novel targeted drugs. Nevertheless, drugs targeting human epidermal growth factor receptor 2 (HER-2), angiogenesis, and other tyrosine kinases also come with unexpected cardiac side effects, including heart failure, hypertension, arterial thrombosis, and arrhythmias, and have mechanisms that are unlike those of classic chemotherapeutic agents. In addition, it is challenging to address some problems, as the existing guidelines need to be more specific, and f...
Source: Cardiovascular Drugs and Therapy - April 13, 2021 Category: Cardiology Source Type: research

An Original Aspirin-Containing Carbonic Anhydrase 9 Inhibitor Overcomes Hypoxia-Induced Drug Resistance to Enhance the Efficacy of Myocardial Protection
ConclusionResults indicate great potential of CAIX inhibitor for further application in myocardial hypoxia injury therapy. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 12, 2021 Category: Cardiology Source Type: research

Correction to: A Non-inferiority, Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus New-Generation Drug-Eluting Stents on Angiographic Outcomes for Coronary De Novo Lesions
A Correction to this paper has been published:https://doi.org/10.1007/s10557-021-07183-1 (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 12, 2021 Category: Cardiology Source Type: research

Association of Low Body Weight with Clinical Outcomes in Elderly Atrial Fibrillation Patients Receiving Apixaban —J-ELD AF Registry Subanalysis
AbstractPurposeAlthough direct oral anticoagulants are effective and safe in preventing stroke in atrial fibrillation (AF) patients with low body weight, data remain limited in AF patients with extremely low body weight (60 kg (n = 1019, 33.7%), 50 –60 kg (n = 1126, 37.2%), and
Source: Cardiovascular Drugs and Therapy - April 8, 2021 Category: Cardiology Source Type: research

Angio-Based Fractional Flow Reserve, Functional Pattern of Coronary Artery Disease, and Prediction of Percutaneous Coronary Intervention Result: a Proof-of-Concept Study
ConclusionOur results suggest that functional patterns of CAD based on pre-PCI QFR trace can predict the functional outcome after PCI.Clinical Trial RegistrationClinicalTrials.gov, number NCT02811796. Date of registration: June 23, 2016. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 8, 2021 Category: Cardiology Source Type: research

Role of Bempedoic Acid in Clinical Practice
AbstractMany patients do not achieve optimal low-density lipoprotein cholesterol (LDL-C) levels with statins alone; others are unable to tolerate statin therapy. Additional non-statin treatment options including ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, and bile acid sequestrants are often necessary to further reduce the risk of atherosclerotic cardiovascular disease. This review provides practical guidance as to the use of bempedoic acid to lower LDL-C and includes direction as to which patients may benefit and advice for safety monitoring during treatment. Bempedoic acid, a new class of agent, ...
Source: Cardiovascular Drugs and Therapy - April 5, 2021 Category: Cardiology Source Type: research

Effects of Angiotensin Receptor-Neprilysin Inhibitor in Arrhythmogenicity Following Left Atrial Appendage Closure in an Animal Model
AbstractPurposeLeft atrial appendage (LAA) closure decreases atrial natriuretic peptide (ANP) levels, which indirectly increases the risk of arrhythmogenicity. We aimed to determine the effect of a combined angiotensin receptor-neprilysin inhibitor (ARNi) on arrhythmogenicity following LAA closure in an animal model.MethodsTwenty-four rabbits were randomized into four groups: (1) control, (2) LAA closure (LAAC), (3) heart failure (HF)-LAAC, and (4) HF-LAAC with sacubitril/valsartan (+ARNi). HF models were developed in the HF-LAAC and HF-LAAC+ARNi groups. Epicardial LAA exclusion was performed in the LAAC, HF-LAAC, and HF-L...
Source: Cardiovascular Drugs and Therapy - April 5, 2021 Category: Cardiology Source Type: research

Risk Stratification and Efficacy of Spironolactone in Patients with Heart Failure with Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial
ConclusionThis simple risk score stratifies patients with HFpEF by their baseline risk of cardiovascular death. Patients at very high risk derive great benefits from spironolactone therapy. This easy-to-use risk score provides a practical tool that can facilitate risk stratification and tailoring therapy for those who benefit most from spironolactone.Trial RegistrationClinicalTrials.gov Identifier: NCT00094302. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - April 1, 2021 Category: Cardiology Source Type: research

Vernakalant for Rapid Cardioversion of Recent-Onset Atrial Fibrillation: Results from the SPECTRUM Study
The objectives of this large, international, multicenter observational study were to determine the safety and effectiveness of intravenous (IV) vernakalant for conversion of AF to sinus rhythm in daily practice.Methods and ResultsConsenting patients with symptomatic recent-onset AF (
Source: Cardiovascular Drugs and Therapy - March 25, 2021 Category: Cardiology Source Type: research

Maxacalcitol (22-Oxacalcitriol (OCT)) Retards Progression of Left Ventricular Hypertrophy with Renal Dysfunction Through Inhibition of Calcineurin-NFAT Activity
ConclusionOur works indicated that OCT retards progression of LVH through calcineurin-NFAT pathway, which reveal a novel aspect of OCT in attenuating pathological LVH. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 25, 2021 Category: Cardiology Source Type: research

Insulin Rescued MCP-1-Suppressed Cholesterol Efflux to Large HDL2 Particles via ABCA1, ABCG1, SR-BI and PI3K/Akt Activation in Adipocytes
In this study, we hypothesize that MCP-1 impairs cholesterol efflux of adipocytes to HDL2 and insulin rescues this process.MethodsWe recruited coronary artery disease (CAD) patients with obesity and overweight to analyze the association between MCP-1 and HDL2-C by Pearson correlation coefficients. We performed [3H]-cholesterol efflux assay to demonstrate the effect of MCP-1 and insulin on cholesterol efflux from 3T3-L1 adipocytes to large HDL2 particles. Western blot, RT-qPCR, cell-surface protein assay, and confocal microscopy were performed to determine the regulatory mechanism.ResultsPlasma MCP-1 concentrations were neg...
Source: Cardiovascular Drugs and Therapy - March 19, 2021 Category: Cardiology Source Type: research

Proton Pump Inhibitor Co-Therapy in Patients with Atrial Fibrillation Treated with Oral Anticoagulants and a Prior History of Upper Gastrointestinal Tract Bleeding
ConclusionAmong patients with AF receiving anticoagulant treatment and with a prior history of upper GIB, PPI co-therapy was associated with a significant reduction in the risk of major GIB in patients treated with rivaroxaban and warfarin. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 17, 2021 Category: Cardiology Source Type: research

Efficacy and Safety of Clinically Driven Low-Dose Treatment with Direct Oral Anticoagulants in Asians with Atrial Fibrillation: a Systematic Review and Meta-analysis
AbstractPurposeAlthough clinically driven low-dose (CDLD) treatment with direct oral anticoagulants (DOACs) is frequently administered to Asian patients with atrial fibrillation, clinical evidence confirming its efficacy remains insufficient. We evaluated the clinical efficacy and safety of CDLD treatment with DOACs compared to on-label dose treatment in Asian patients with atrial fibrillation and assessed the differences in the baseline characteristics between patients receiving these treatments.MethodsWe searched the MEDLINE, CENTRAL, EMBASE, Web of Science, and Scopus databases for articles from inception through July 2...
Source: Cardiovascular Drugs and Therapy - March 16, 2021 Category: Cardiology Source Type: research

A Non-inferiority, Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus New-Generation Drug-Eluting Stents on Angiographic Outcomes for Coronary De Novo Lesions
ConclusionsIn this prospective study, the DCB only strategy for de novo lesion was non-inferior to the new-generation DES in terms of 9-month late lumen loss. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 13, 2021 Category: Cardiology Source Type: research

Report of the British Society for Cardiovascular Research Inaugural Online Autumn Meeting 2020
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 13, 2021 Category: Cardiology Source Type: research

Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction
Conclusion: New genetics-guided pharmacotherapies to reduce levels of triglycerides and TGRLs and thus reduce risk of CVD have been developed and will be discussed here. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 12, 2021 Category: Cardiology Source Type: research

Low-dose Dasatinib Ameliorates Hypertrophic Cardiomyopathy in Noonan Syndrome with Multiple Lentigines
ConclusionThese data demonstrate that low-dose dasatinib exhibits desirable therapeutic PK properties that is sufficient for effective target engagement to ameliorate HCM progression in NSML mice. These data demonstrate that low-dose dasatinib treatment may be an effective therapy against HCM in NSML patients. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 10, 2021 Category: Cardiology Source Type: research

Restoring Perivascular Adipose Tissue Function in Obesity Using Exercise
ConclusionLoss of neutrally mediated PVAT anti-contractile function in obesity will contribute to the development of hypertension and type II diabetes. Exercise training will restore function and treat the vascular complications of obesity. (Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 9, 2021 Category: Cardiology Source Type: research

Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease
AbstractPurposeTo assess real-world data on the clinical implementation of sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) in cardiovascular patients and to investigate barriers to prescribe these agents.MethodsPatients presenting with coronary artery disease (CAD) and type 2  diabetes mellitus (T2DM) between 01/2014 and 04/2020 were included in the present analysis and followed prospectively. All first-time prescriptions of SGLT2i and GLP-1RA were identified.ResultsAmong 1498 patients with CAD and T2DM, 17.6% of patients received an SGLT2i and 5.5% a GLP-1RA....
Source: Cardiovascular Drugs and Therapy - March 5, 2021 Category: Cardiology Source Type: research

Is there a Future for Remote Ischemic Conditioning in Acute Myocardial Infarction?
(Source: Cardiovascular Drugs and Therapy)
Source: Cardiovascular Drugs and Therapy - March 5, 2021 Category: Cardiology Source Type: research